Ms. Dawn Svoronos (Graham) concluded her twenty-three-year commercial career with Merck & Co. Inc as President of Europe & Canada, a region comprised of thirty-seven EU and EU accession countries and Canada. Prior to that role, Ms. Svoronos served as President of Merck Frosst in Canada and Vice-President of Merck in the Asia Pacific. In addition to her significant global commercial experience, Ms. Svoronos has served as an advisor to a number of organizations, including Medivation, a medical technology company that acquires and develops early-stage pharmaceutical and medical device technology. Ms. Svoronos also currently serves on the Board of Directors for three publicly-traded companies: PTC Therapeutics in New Jersey, Theratechnologies Inc. in Montreal, Quebec, Canada, and Xenon Pharmaceuticals in Vancouver, British Columbia, Canada.